Since its approval, it has revolutionized therapy for patients with ALK‐rearranged non‐small cell lung cancer (NSCLC), a subtype comprising 4%–7% of all NSCLC cases [2, 3]. This evidence concerns the gene ALK and non-small cell lung carcinoma.